EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 41 / No 2 (Février 2025) Med Sci (Paris), 41 2 (2025) 187-189 References
Issue
Med Sci (Paris)
Volume 41, Number 2, Février 2025
Chroniques génomiques
Page(s) 187 - 189
Section Forum
DOI https://doi.org/10.1051/medsci/2025017
Published online 03 March 2025
  1. Jordan B. Édition de gènes in vivo et thérapie génique Med Sci (Paris) 2021 ; 37 : 933–5. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Chneiweiss H. Premiers succès et nouveaux enjeux de l’édition du génome en thérapeutique humaine. Med Sci (Paris) 2023 ; 39 : 589–90. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Jordan B. Thérapie génique in vivo : une approche modulaire. Med Sci (Paris) 2024 ; 40 : 677–9 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. Center for Biologics Evaluation and Research. Approved cellular and gene therapy products. FDA, 21 Nov. 2024. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-an-gene-therapy-products [Google Scholar]
  5. Jordan B. Une thérapie très attendue et un prix exorbitant ! Med Sci (Paris) 2023 ; 39 : 187–90 [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Wong CH, Li D, Wang N, et al. The estimated annual financial impact of gene therapy in the United States. Gene Ther 2023 : 30 : 761–73 [CrossRef] [PubMed] [Google Scholar]
  7. Witkowsky L, Norstad M, Glynn AR, Kliegman M. Towards affordable CRISPR genomic therapies: a task force convened by the Innovative Genomics Institute Gene Ther 2023 ;30 : 747–52. [CrossRef] [PubMed] [Google Scholar]
  8. The Innovative Genomics Institute (2023). Making genetic therapies affordable and accessible. [white paper]. https://innovativegenomics.org/making-genetic-therapies-affordable-and-accessible/ [Google Scholar]
  9. Kliegman M, Zaghlula M, Abrahamson S, et al. A roadmap for affordable genetic medicines. Nature 2024 ; 634 : 307–14 [CrossRef] [PubMed] [Google Scholar]
  10. Dredge C, Scholtes S. The health care utility model: a novel approach to doing business. NEJM Catalyst (8 July 2021). https://catalyst.nejm.org/doi/full/10.1056/CAT.21.0189 [Google Scholar]
  11. Fox T, Bueren J, Candotti F, et al., AGORA Initiative. Access to gene therapy for rare diseases when commercialization is not fit for purpose. Nat Med 2023 ;29 :518–9 [Google Scholar]
  12. Fox TA, Booth C. Improving access to gene therapy for rare diseases. Dis Model Mech 2024 ; 17 : doi: 10.1242/dmm.050623 [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.